Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 84, Issue 6, Pages 734-740Publisher
WILEY
DOI: 10.1038/clpt.2008.187
Keywords
-
Categories
Funding
- Department of Health and Human Services, National Institutes of Health Public Health Service [NCRR 1K12RR017613, NICHD 5U10HD031318, NICHD 1U10 HD45993, NCRR 1K24RR019729]
Ask authors/readers for more resources
Adolescents infected with human immunodeficiency virus (HIV) represent a heterogeneous group of pubertal children and young adults. Antiretroviral therapy (ART) in adolescents is complex and depends on multiple factors. The continued use of higher (weight- or surface-based) pediatric doses can result in potentially toxic drug exposure, whereas early introduction of lower adult doses can lead to the development of drug resistance and virologic failure. The physiological and psychosocial changes during puberty create strong grounds for an individualized therapeutic approach in HIV-infected adolescents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available